Online inquiry

IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12690MR)

This product GTTS-WQ12690MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets DLL4 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_019074.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 54567
UniProt ID Q9NR61
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12690MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11203MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ15927MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ8766MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA IBI-101
GTTS-WQ6222MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CR4098
GTTS-WQ1350MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-806
GTTS-WQ6893MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA E-6011
GTTS-WQ3305MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ASN-100
GTTS-WQ6844MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA DT-IL-3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW